pNfH is a promising biomarker for ALS

Area of Science:

• Neuroscience
• Biomarker Discovery
• Neurology

Background:

• Amyotrophic Lateral Sclerosis (ALS) lacks definitive early diagnostic biomarkers.
• Neurofilaments, particularly phosphorylated neurofilament heavy subunit (pNfH), are abundant in neurons and may indicate neuronal damage.

Purpose of the Study:

• To investigate the potential of CSF pNfH as a diagnostic and prognostic biomarker for ALS.
• To evaluate the diagnostic accuracy of pNfH in distinguishing ALS from control groups.

Main Methods:

• Enzyme-linked immunosorbent assay (ELISA) was used to measure CSF pNfH levels.
• 150 ALS patients and 140 controls (including benign, ALS mimics, and other neurodegenerative conditions) were analyzed.

Main Results:

• CSF pNfH levels were significantly elevated (7-fold) in ALS patients compared to benign controls.
• A 10-fold elevation in pNfH was observed in ALS compared to ALS mimics and other neurological conditions.
• pNfH demonstrated 90% sensitivity and 87% specificity for ALS diagnosis.
• An inverse correlation was found between CSF pNfH levels and ALS disease duration.

Conclusions:

• CSF pNfH is a highly accurate biomarker for diagnosing ALS.
• pNfH shows potential as a prognostic marker, correlating with disease duration.
• pNfH may facilitate earlier ALS diagnosis and accelerate drug development.